BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16551870)

  • 1. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.
    Gagnon JF; Bernard O; Villeneuve L; Têtu B; Guillemette C
    Clin Cancer Res; 2006 Mar; 12(6):1850-8. PubMed ID: 16551870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells.
    Bélanger AS; Tojcic J; Harvey M; Guillemette C
    BMC Mol Biol; 2010 Jan; 11():9. PubMed ID: 20096102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11.
    Xie FW; Peng YH; Wang WW; Chen X; Chen X; Li J; Yu ZY; Ouyang XN
    Biomed Pharmacother; 2014 Sep; 68(7):825-31. PubMed ID: 25260839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells.
    Xie FW; Peng YH; Chen X; Chen X; Li J; Yu ZY; Wang WW; Ouyang XN
    Biomed Pharmacother; 2014 Feb; 68(1):31-7. PubMed ID: 24439671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney.
    Oda S; Fukami T; Yokoi T; Nakajima M
    Drug Metab Dispos; 2013 Oct; 41(10):1738-43. PubMed ID: 23401472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
    Girard H; Villeneuve L; Court MH; Fortier LC; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
    Drug Metab Dispos; 2006 Jul; 34(7):1220-8. PubMed ID: 16595709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
    Jinno H; Tanaka-Kagawa T; Hanioka N; Saeki M; Ishida S; Nishimura T; Ando M; Saito Y; Ozawa S; Sawada J
    Drug Metab Dispos; 2003 Jan; 31(1):108-13. PubMed ID: 12485959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
    Zou B; Chim CS; Zeng H; Leung SY; Yang Y; Tu SP; Lin MC; Wang J; He H; Jiang SH; Sun YW; Yu LF; Yuen ST; Kung HF; Wong BC
    Gastroenterology; 2006 Dec; 131(6):1835-43. PubMed ID: 17087954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer.
    Obata T; Toyota M; Satoh A; Sasaki Y; Ogi K; Akino K; Suzuki H; Murai M; Kikuchi T; Mita H; Itoh F; Issa JP; Tokino T; Imai K
    Clin Cancer Res; 2003 Dec; 9(17):6410-8. PubMed ID: 14695142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas.
    Zhong S; Tang MW; Yeo W; Liu C; Lo YM; Johnson PJ
    Clin Cancer Res; 2002 Apr; 8(4):1087-92. PubMed ID: 11948118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21.
    Derks S; Bosch LJ; Niessen HE; Moerkerk PT; van den Bosch SM; Carvalho B; Mongera S; Voncken JW; Meijer GA; de Bruïne AP; Herman JG; van Engeland M
    Carcinogenesis; 2009 Jun; 30(6):1041-8. PubMed ID: 19329758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
    Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K
    Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
    Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
    Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.
    Zhao W; Soejima H; Higashimoto K; Nakagawachi T; Urano T; Kudo S; Matsukura S; Matsuo S; Joh K; Mukai T
    J Biochem; 2005 Mar; 137(3):431-40. PubMed ID: 15809347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
    Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
    J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of promoter methylation in regulation of the mammalian heparanase gene.
    Shteper PJ; Zcharia E; Ashhab Y; Peretz T; Vlodavsky I; Ben-Yehuda D
    Oncogene; 2003 Oct; 22(49):7737-49. PubMed ID: 14586400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
    Raynal C; Pascussi JM; Leguelinel G; Breuker C; Kantar J; Lallemant B; Poujol S; Bonnans C; Joubert D; Hollande F; Lumbroso S; Brouillet JP; Evrard A
    Mol Cancer; 2010 Mar; 9():46. PubMed ID: 20196838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
    Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M
    J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.